Catalytic Cleavage of Disulfide Bonds in Small Molecules and Linkers of Antibody-Drug Conjugates

被引:32
|
作者
Zhang, Donglu [1 ]
Fourie-O'Donohue, Aimee [2 ]
Dragovich, Peter S. [3 ]
Pillow, Thomas H. [3 ]
Sadowsky, Jack D. [4 ]
Kozak, Katherine R. [2 ]
Cass, Robert T. [1 ]
Liu, Liling [1 ]
Deng, Yuzhong [1 ]
Liu, Yichin [2 ]
Hop, Cornelis E. C. A. [1 ]
Khojasteh, S. Cyrus [1 ]
机构
[1] Genentech Inc, Drug Metab & Pharmacokinet, 1 DNA Way MS 412a, San Francisco, CA 94080 USA
[2] Genentech Inc, Biochem & Cellular Pharmacol, San Francisco, CA 94080 USA
[3] Genentech Inc, Discovery Chem, San Francisco, CA 94080 USA
[4] Genentech Inc, Prot Chem, San Francisco, CA 94080 USA
关键词
SITE-SPECIFIC CONJUGATION; ANTICANCER PRODRUGS; THIOREDOXIN; CYSTEINE; GLUTATHIONE; DELIVERY;
D O I
10.1124/dmd.118.086132
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In cells, catalytic disulfide cleavage is an essential mechanism in protein folding and synthesis. However, detailed enzymatic catalytic mechanism relating cleavage of disulfide bonds in xenobiotics is not well understood. This study reports an enzymatic mechanism of cleavage of disulfide bonds in xenobiotic small molecules and antibody conjugate (ADC) linkers. The chemically stable disulfide bonds in substituted disulfide-containing pyrrolobenzodiazepine (PBD, pyrrolo[2,1-c][1,4]benzodiazepine) monomer prodrugs in presence of glutathione or cysteine were found to be unstable in incubations in whole blood of humans and rats. It was shown the enzymes involved were thioredoxin (TRX) and glutaredoxin (GRX). For a diverse set of drug-linker conjugates, we determined that TRX in the presence of TRX-reductase and NADPH generated the cleaved products that are consistent with catalytic disulfide cleavage and linker immolation. GRX was less rigorously studied; in the set of compounds studied, its role in the catalytic cleavage was also confirmed. Collectively, these in vitro experiments demonstrate that TRX as well as GRX can catalyze the cleavage of disulfide bonds in both small molecules and linkers of ADCs.
引用
收藏
页码:1156 / 1163
页数:8
相关论文
共 50 条
  • [21] Affinity-bound antibody-drug conjugates
    Nervig, Christine S.
    Owen, Shawn C.
    NATURE BIOMEDICAL ENGINEERING, 2019, 3 (11) : 850 - 851
  • [22] Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
    Donaghy, Heather
    MABS, 2016, 8 (04) : 659 - 671
  • [23] Recent Advances in Drug-Antibody Ratio Determination of Antibody-Drug Conjugates
    Matsuda, Yutaka
    Mendelsohn, Brian A.
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2021, 69 (10) : 976 - 983
  • [24] Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody-Drug Conjugates
    Zhang, Donglu
    Pillow, Thomas H.
    Ma, Yong
    dela Cruz-Chuh, Josefa
    Kozak, Katherine R.
    Sadowsky, Jack D.
    Philips, Gail D. Lewis
    Guo, Jun
    Darwish, Martine
    Fan, Peter
    Chen, Jingtian
    He, Changrong
    Wang, Tao
    Yao, Hui
    Xu, Zijin
    Chen, Jinhua
    Wai, John
    Pei, Zhonghua
    Hop, Cornelis E. C. A.
    Khojasteh, S. Cyrus
    Dragovich, Peter S.
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (11): : 988 - 993
  • [25] Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies
    Goodman, Rachel
    Johnson, Douglas B.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (10) : 1428 - 1442
  • [26] Dual-payload antibody-drug conjugates: Taking a dual shot
    Tao, Junjie
    Gu, Yilin
    Zhou, Wei
    Wang, Yuxi
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 281
  • [27] Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability
    Singh, Satish K.
    Luisi, Donna L.
    Pak, Roger H.
    PHARMACEUTICAL RESEARCH, 2015, 32 (11) : 3541 - 3571
  • [28] Antibody-drug conjugates: Current status and future perspectives
    Gebleux, Remy
    Casi, Giulio
    PHARMACOLOGY & THERAPEUTICS, 2016, 167 : 48 - 59
  • [29] Homogeneous multi-payload antibody-drug conjugates
    Journeaux, Toby
    Bernardes, Goncalo J. L.
    NATURE CHEMISTRY, 2024, 16 (06) : 854 - 870
  • [30] Evolving Strategies for Target Selection for Antibody-Drug Conjugates
    Marc Damelin
    Wenyan Zhong
    Jeremy Myers
    Puja Sapra
    Pharmaceutical Research, 2015, 32 : 3494 - 3507